Gold tier: mechanically validated evidence, with its primary source.
49 evidence items · page 1 / 2
11,017 patients11,017 patients were enrolled in an observational study on dihydroartemisinin-piperaquine for uncomplicated malaria in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
Malaria was more prevalent in children without HIV.
Ghanapaludismepublished 2018Malaria journalPubMeddocument of 4 observations
324 per_1000The malaria incidence averted was 324 per 1,000 children aged 12–59 months in 2020 in the implementing area.
Ghanapaludismeobserved 2020published 2024Malaria journalPubMeddocument of 4 observations
490 cases_averted_per_1000_full_dose_equivalentsIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 RTS,S full-dose equivalents at month 32 post-dose 1, was 490 for group R012-14-26.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
287 per_1000The malaria incidence averted was 287 per 1,000 children aged 12–59 months in 2022 in the implementing area.
Ghanapaludismeobserved 2022published 2024Malaria journalPubMeddocument of 4 observations
28 %The prevalence of placental malaria was 28.0% among 2646 pregnant women with malaria in Burkina Faso, Ghana, Malawi, and Zambia.
Burkina Faso · Ghana · Malawi · Zambiepaludismepublished 2019Malaria journaleurope_pmcdocument of 6 observations
0.41 %A 1% increase in malaria morbidity reduces economic growth by 0.41% in Ghana.
GhanapaludismeHAL · Unilimdocument of 40 observations
Three sub-Saharan African countries — Ghana, Kenya, and Malawi — participated in a large-scale clinical study supervised by the WHO to assess the feasibility of vaccination against malaria in children.
Ghana · Kenya · MalawipaludismeHAL · Unilimdocument of 84 observations
11,097 patientsA total of 11,097 patients were screened for confirmed uncomplicated malaria in an observational study conducted in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
38 %In a phase 2b trial in Ghana and Kenya, vaccine efficacy of the RTS,S malaria vaccine against clinical malaria (all episodes) at month 32 post-dose 1 ranged from 38% (95% confidence interval: 24%–49%) to 53% (95% confidence interval: 42%–62%).
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
74.7 %In Ghana, prevalence of hemoglobin genotypes was 74.7% for AA, 14.7% for AC, 9.1% for AS, and 0.9% for SS.
GhanapaludismeHAL · Unilimdocument of 81 observations
7.12 nMArtemether was less potent against Plasmodium malariae than Plasmodium falciparum in Ghana, with IC50 values of 7.12 nM versus 2.15 nM.
Ghanapaludismepublished 2025Microbiology spectrumeurope_pmcdocument of 5 observations
2,112 cases_averted_per_1000_childrenIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 children vaccinated at month 32 post-dose 1, was 2112 for group Fx017-20-32.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
12.7 %Plasmodium malariae was detected in 12.7% of the 142 malaria-positive participants in Mpraeso, Ghana.
Ghanapaludismeobserved 2014published 2017Malaria journalPubMeddocument of 4 observations
25 %Malaria parasitemia prevalence was 25% among people living with HIV in the rural area of Atibie, Ghana.
Ghanapaludismepublished 2018Acta tropicaPubMeddocument of 4 observations
2,450 cases_averted_per_1000_childrenIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 children vaccinated at month 32 post-dose 1, was 2450 for group R012-14-26.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
47.9 %In Ghana, malaria prevalence among pregnant women at first antenatal care visit was 47.9% (622 of 1298).
Ghanapaludismeobserved between May, 2010, and August, 2014PubMeddocument of 8 observations
874 cases_averted_per_1000_full_dose_equivalentsIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 RTS,S full-dose equivalents at month 32 post-dose 1, was 874 for group Fx012-14-26.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
96.1 %96.1% of enrolled patients met protocol requirements for analysis in an observational study on dihydroartemisinin-piperaquine for uncomplicated malaria in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
Ghana, Kenya, and Malawi were the first countries to introduce the RTS,S/AS01 malaria vaccine into their childhood immunization programmes in 2019 as part of a pilot programme called the Malaria Vaccine Implementation Programme (MVIP).
Ghana · Kenya · Malawipaludismeobserved 2019published 2025Malaria journalPubMeddocument of 2 observations
445,000 deathsIn 2016, there were an estimated 445,000 malaria deaths.
Ghanapaludismeobserved 2016HAL · Unilimdocument of 40 observations
10.38 nMAtovaquone was less potent against Plasmodium malariae than Plasmodium falciparum in Ghana, with IC50 values of 10.38 nM versus 2.51 nM.
Ghanapaludismepublished 2025Microbiology spectrumeurope_pmcdocument of 5 observations
332 patients332 patients withdrew from an observational study on dihydroartemisinin-piperaquine for uncomplicated malaria in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
2,273 cases_averted_per_1000_childrenIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 children vaccinated at month 32 post-dose 1, was 2273 for group Fx012-14-26.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
55 %In Ghana, the household is responsible for 55% of the malaria treatment cost.
GhanapaludismeHAL · Unilimdocument of 40 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.